Zacks: Analysts Anticipate Zimmer Biomet Holdings, Inc. (ZBH) to Post $1.77 Earnings Per Share
Equities research analysts expect Zimmer Biomet Holdings, Inc. (NYSE:ZBH) to announce earnings per share (EPS) of $1.77 for the current fiscal quarter, according to Zacks. Ten analysts have provided estimates for Zimmer Biomet Holdings’ earnings, with the highest EPS estimate coming in at $1.93 and the lowest estimate coming in at $1.73. Zimmer Biomet Holdings posted earnings per share of $1.79 during the same quarter last year, which indicates a negative year over year growth rate of 1.1%. The firm is scheduled to issue its next earnings results on Monday, October 30th.
According to Zacks, analysts expect that Zimmer Biomet Holdings will report full-year earnings of $8.26 per share for the current financial year, with EPS estimates ranging from $8.20 to $8.55. For the next fiscal year, analysts expect that the firm will report earnings of $8.83 per share, with EPS estimates ranging from $8.55 to $9.38. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow Zimmer Biomet Holdings.
Zimmer Biomet Holdings (NYSE:ZBH) last posted its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share for the quarter, missing the consensus estimate of $2.10 by $0.02. The firm had revenue of $1.95 billion for the quarter, compared to the consensus estimate of $1.95 billion. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The firm’s revenue was up 1.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.02 EPS.
A number of analysts recently commented on the company. Royal Bank Of Canada reiterated an “outperform” rating and set a $140.00 price objective on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. Wells Fargo & Company reissued a “market weight” rating on shares of Zimmer Biomet Holdings in a report on Friday, July 14th. Jefferies Group LLC reissued a “buy” rating and set a $148.00 price target on shares of Zimmer Biomet Holdings in a report on Friday, June 30th. Piper Jaffray Companies reissued a “buy” rating and set a $135.00 price target on shares of Zimmer Biomet Holdings in a report on Friday, July 28th. Finally, Oppenheimer Holdings Inc. set a $137.00 price target on Zimmer Biomet Holdings and gave the company a “buy” rating in a report on Friday, July 28th. Four investment analysts have rated the stock with a sell rating, seven have issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $136.75.
Zimmer Biomet Holdings (NYSE:ZBH) opened at 115.70 on Friday. The company has a market cap of $23.39 billion, a P/E ratio of 32.95 and a beta of 1.21. The stock’s 50 day moving average price is $116.64 and its 200 day moving average price is $120.78. Zimmer Biomet Holdings has a 1-year low of $95.63 and a 1-year high of $133.49.
The company also recently announced a quarterly dividend, which will be paid on Friday, October 27th. Investors of record on Friday, September 22nd will be given a $0.24 dividend. The ex-dividend date is Thursday, September 21st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.83%. Zimmer Biomet Holdings’s dividend payout ratio is currently 27.59%.
In related news, VP Tony W. Collins sold 16,986 shares of the business’s stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $121.74, for a total value of $2,067,875.64. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Sang Yi sold 17,731 shares of the business’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $124.56, for a total value of $2,208,573.36. The disclosure for this sale can be found here. 1.07% of the stock is currently owned by insiders.
Hedge funds have recently modified their holdings of the business. Bronfman E.L. Rothschild L.P. raised its position in Zimmer Biomet Holdings by 25.3% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock valued at $106,000 after purchasing an additional 167 shares during the period. Parkside Financial Bank & Trust raised its position in Zimmer Biomet Holdings by 2.7% during the first quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock valued at $102,000 after purchasing an additional 22 shares during the period. BB&T Investment Services Inc. purchased a new stake in Zimmer Biomet Holdings during the second quarter valued at approximately $144,000. Parallel Advisors LLC raised its position in Zimmer Biomet Holdings by 20.8% during the first quarter. Parallel Advisors LLC now owns 1,157 shares of the medical equipment provider’s stock valued at $138,000 after purchasing an additional 199 shares during the period. Finally, IHT Wealth Management LLC raised its position in Zimmer Biomet Holdings by 28.4% during the first quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock valued at $139,000 after purchasing an additional 256 shares during the period. Institutional investors and hedge funds own 85.48% of the company’s stock.
About Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.